FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4233544264> ?p ?o ?g. }

• W4233544264 endingPage "S1826" @default.
• W4233544264 startingPage "S1826" @default.
• W4233544264 abstract "Patients with ALK-positive NSCLC have seen significant advances and increased options in ALK targeted therapies recently, and therefore rely on high quality, robust ALK status testing. Fluorescence in-situ hybridization (FISH) and immunohistochemistry (IHC) are the most common methods to determine ALK status for ALK tyrosine kinase inhibitor (TKI) treatment. However, availability of clinical outcome data from randomized trials linked directly to specific methods is limited. The ALEX trial (BO28984, NCT02075840) provides a unique dataset to assess ALK IHC- and FISH-based assays regarding clinical outcome for alectinib and crizotinib, particularly for the subset of patients with IHC-positive/FISH-negative NSCLC. The VENTANA ALK (D5F3) CDx Assay (ALK IHC) performed in central laboratories was used as an enrollment assay for the selection of patients with ALK-positive NSCLC for inclusion in the ALEX trial. Additional samples from these patients were retrospectively tested in central laboratories with the Vysis ALK Break Apart FISH Probe Kit (ALK FISH). Overall, 303 patients all with ALK IHC-positive NSCLC were randomized in the ALEX trial, of those 242 patients also had a valid ALK FISH result, with 203 patients having ALK FISH-positive disease and 39 patients having ALK FISH-negative disease (alectinib, n=21; crizotinib, n=18). For 61 of 303 (20.1%) patients with an ALK IHC-positive result, a valid ALK FISH result could not be obtained due to the test leading to an uninformative FISH result (10.9%), or not having adequate/no tissue available (9.2%). Ventana IHC staining success rates were higher than for Vysis FISH testing for the ALEX samples. Exploratory analysis of investigator-assessed progression-free survival (PFS) in patients with a FISH-positive result (HR 0.40, 95% CI 0.27–0.61; p<0.0001; median not reached [alectinib] versus 12.7 months [crizotinib]) was consistent with the primary endpoint analysis in the Ventana ALK IHC-positive population. Patient outcome data show that 28% of central ALK IHC-positive/ALK FISH-negative samples were from patients who responded to ALK TKI treatment (complete response or partial response) and 33% had stable disease according to investigator assessment. This analysis shows that ALK IHC is a robust testing approach, which may identify more patients with a valid ALK testing result who benefit from ALK TKI treatment than ALK FISH testing. While PFS of patients with ALK FISH-positive NSCLC was similar to that of patients with ALK IHC-positive NSCLC, the analysis also revealed that the majority of patients with ALK IHC-positive/ALK FISH-negative NSCLC may derive clinical benefit from ALK TKI treatment." @default.
• W4233544264 created "2022-05-12" @default.
• W4233544264 creator A5003664573 @default.
• W4233544264 creator A5008407441 @default.
• W4233544264 creator A5009463747 @default.
• W4233544264 creator A5016911330 @default.
• W4233544264 creator A5031167575 @default.
• W4233544264 creator A5035562927 @default.
• W4233544264 creator A5057132218 @default.
• W4233544264 creator A5057815309 @default.
• W4233544264 creator A5064163261 @default.
• W4233544264 creator A5066717752 @default.
• W4233544264 creator A5068540733 @default.
• W4233544264 creator A5071712987 @default.
• W4233544264 creator A5082517668 @default.
• W4233544264 creator A5082778307 @default.
• W4233544264 creator A5083698345 @default.
• W4233544264 creator A5087923582 @default.
• W4233544264 date "2017-11-01" @default.
• W4233544264 modified "2023-09-30" @default.
• W4233544264 title "MA 07.01 Patients with ALK IHC-Positive/FISH-Negative NSCLC Benefit from ALK TKI Treatment: Response Data from the Global ALEX Trial" @default.
• W4233544264 doi "https://doi.org/10.1016/j.jtho.2017.09.503" @default.
• W4233544264 hasPublicationYear "2017" @default.
• W4233544264 type Work @default.
• W4233544264 citedByCount "1" @default.
• W4233544264 countsByYear W42335442642022 @default.
• W4233544264 crossrefType "journal-article" @default.
• W4233544264 hasAuthorship W4233544264A5003664573 @default.
• W4233544264 hasAuthorship W4233544264A5008407441 @default.
• W4233544264 hasAuthorship W4233544264A5009463747 @default.
• W4233544264 hasAuthorship W4233544264A5016911330 @default.
• W4233544264 hasAuthorship W4233544264A5031167575 @default.
• W4233544264 hasAuthorship W4233544264A5035562927 @default.
• W4233544264 hasAuthorship W4233544264A5057132218 @default.
• W4233544264 hasAuthorship W4233544264A5057815309 @default.
• W4233544264 hasAuthorship W4233544264A5064163261 @default.
• W4233544264 hasAuthorship W4233544264A5066717752 @default.
• W4233544264 hasAuthorship W4233544264A5068540733 @default.
• W4233544264 hasAuthorship W4233544264A5071712987 @default.
• W4233544264 hasAuthorship W4233544264A5082517668 @default.
• W4233544264 hasAuthorship W4233544264A5082778307 @default.
• W4233544264 hasAuthorship W4233544264A5083698345 @default.
• W4233544264 hasAuthorship W4233544264A5087923582 @default.
• W4233544264 hasBestOaLocation W42335442641 @default.
• W4233544264 hasConcept C104317684 @default.
• W4233544264 hasConcept C117643217 @default.
• W4233544264 hasConcept C126322002 @default.
• W4233544264 hasConcept C143998085 @default.
• W4233544264 hasConcept C204232928 @default.
• W4233544264 hasConcept C2776232967 @default.
• W4233544264 hasConcept C2776256026 @default.
• W4233544264 hasConcept C2777542201 @default.
• W4233544264 hasConcept C2778347629 @default.
• W4233544264 hasConcept C2779220645 @default.
• W4233544264 hasConcept C2779422266 @default.
• W4233544264 hasConcept C30481170 @default.
• W4233544264 hasConcept C55493867 @default.
• W4233544264 hasConcept C71924100 @default.
• W4233544264 hasConcept C86803240 @default.
• W4233544264 hasConceptScore W4233544264C104317684 @default.
• W4233544264 hasConceptScore W4233544264C117643217 @default.
• W4233544264 hasConceptScore W4233544264C126322002 @default.
• W4233544264 hasConceptScore W4233544264C143998085 @default.
• W4233544264 hasConceptScore W4233544264C204232928 @default.
• W4233544264 hasConceptScore W4233544264C2776232967 @default.
• W4233544264 hasConceptScore W4233544264C2776256026 @default.
• W4233544264 hasConceptScore W4233544264C2777542201 @default.
• W4233544264 hasConceptScore W4233544264C2778347629 @default.
• W4233544264 hasConceptScore W4233544264C2779220645 @default.
• W4233544264 hasConceptScore W4233544264C2779422266 @default.
• W4233544264 hasConceptScore W4233544264C30481170 @default.
• W4233544264 hasConceptScore W4233544264C55493867 @default.
• W4233544264 hasConceptScore W4233544264C71924100 @default.
• W4233544264 hasConceptScore W4233544264C86803240 @default.
• W4233544264 hasIssue "11" @default.
• W4233544264 hasLocation W42335442641 @default.
• W4233544264 hasOpenAccess W4233544264 @default.
• W4233544264 hasPrimaryLocation W42335442641 @default.
• W4233544264 hasRelatedWork W2022245544 @default.
• W4233544264 hasRelatedWork W2554166766 @default.
• W4233544264 hasRelatedWork W2785869955 @default.
• W4233544264 hasRelatedWork W2891240143 @default.
• W4233544264 hasRelatedWork W2927866609 @default.
• W4233544264 hasRelatedWork W3008609132 @default.
• W4233544264 hasRelatedWork W3035529108 @default.
• W4233544264 hasRelatedWork W4206126385 @default.
• W4233544264 hasRelatedWork W4226257711 @default.
• W4233544264 hasRelatedWork W4230773384 @default.
• W4233544264 hasVolume "12" @default.
• W4233544264 isParatext "false" @default.
• W4233544264 isRetracted "false" @default.
• W4233544264 workType "article" @default.